United States · Pharmaceuticals startup

Proteus Digital Health, Inc

Welcome to Proteus Digital Health, a leading innovator spearheading the Digital Medicines revolution.

Listed

PharmaceuticalsRedwood City, United States

About Proteus Digital Health, Inc

Welcome to Proteus Digital Health, a leading innovator spearheading the Digital Medicines revolution.

Join our unique collection of innovative engineers, scientists, designers, developers, clinicians, and other digital health pioneers, and assist us with achieving our compelling vision, “Healthcare for Everyone, Everywhere.” Proteus is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicine includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making, and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicine is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved. For more information, visit www.proteus.com.

Founders and team

From the SEC filings it signed: 8 on the team.

  • Andrew M. ThompsonExecutive Officer, Directori
  • Anthony J. LevitanExecutive Officeri
  • Ben M. CostelloExecutive Officeri
  • David M. O'ReillyExecutive Officeri
  • Donald J. CowlingExecutive Officeri
  • George M. SavageExecutive Officeri
  • Mark J. ZdeblickExecutive Officeri
  • Markus J. ChristenExecutive Officeri

On the board, as filediAlan J. LevyFrank J. FischerImmanuel J. ThangarajJonathan J. SymondsMyrtle J. PotterRobert J. EpsteinRyan J. Schwarz

On a portfolio page

Investors who name them

Each firm lists Proteus Digital Health, Inc on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Pharmaceuticals in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Proteus Digital Health, Inc in front of investors. Or tell us what we have wrong.